DrugPatentWatch Database Preview
ZERVIATE Drug Profile
When do Zerviate patents expire, and when can generic versions of Zerviate launch?
Zerviate is a drug marketed by Eyevance and is included in one NDA. There are four patents protecting this drug.
This drug has fifteen patent family members in five countries.
The generic ingredient in ZERVIATE is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and sixty-five suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.
Summary for ZERVIATE
| International Patents: | 15 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 66 |
| Patent Applications: | 4,115 |
| Formulation / Manufacturing: | see details |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for ZERVIATE |
| DailyMed Link: | ZERVIATE at DailyMed |
Medical Subject Heading (MeSH) Categories for ZERVIATE
Synonyms for ZERVIATE
| (2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid |
| (2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid |
| (2-{4-[(4-Chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid (2HCl) |
| [(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid |
| [2-[4-[(4-Chlorophenyl)-phenyl methyl]-1-piperazinyl] ethoxy] acetic acid |
| [2-[4-[(4-chlorophenyl)phenylmethyl] 1-piperazinyl]-ethoxy] acetic acid |
| [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-ethoxy]acetic acid |
| [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid |
| 110271-EP2284166A1 |
| 110271-EP2298415A1 |
| 2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid |
| 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid |
| 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazino}ethoxy)acetic acid |
| 2-(2-{4-[(4-chlorophenyl)phenylmethyl]piperazinyl}ethoxy)acetic acid |
| 2-[2-[4-[(4-chlorophenyl)-phenyl-methyl]piperazin-1-yl]ethoxy]acetic acid |
| 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid |
| 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid |
| 24161-EP2272832A1 |
| 24161-EP2281815A1 |
| 24161-EP2295409A1 |
| 24161-EP2301933A1 |
| 24161-EP2305640A2 |
| 24161-EP2311827A1 |
| 24161-EP2314590A1 |
| 81C510 |
| 83881-51-0 |
| 83881-52-1 (di-hydrochloride) |
| A10107 |
| AB0019096 |
| AC-5545 |
| AC1L1E7T |
| AC1Q768B |
| Acetic acid, (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- |
| Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- |
| AKOS003589059 |
| AKOS021729457 |
| Alerlisin |
| AN-10906 |
| AN-15756 |
| BBL009968 |
| BCP08787 |
| BCP28477 |
| BDBM22890 |
| Benaday |
| BPBio1_000469 |
| BRD-A42571354-300-05-4 |
| BRD-A42571354-300-07-0 |
| BSPBio_000425 |
| BSPBio_002302 |
| C-5854 |
| C07778 |
| C21H25ClN2O3 |
| CC0153 |
| Cetiderm (TN) |
| Cetirizin |
| Cetirizina |
| Cetirizina [Spanish] |
| cetirizine |
| Cetirizine (INN) |
| Cetirizine [INN:BAN] |
| CETIRIZINE HYDROCHLORIDE |
| CetirizineHydrochloride |
| Cetirizinum |
| Cetirizinum [Latin] |
| Cetrizide |
| Cetrizine Dihcl |
| Cetrizine Hcl |
| Cetryn |
| CHEBI:3561 |
| CHEMBL1000 |
| CPD001453715 |
| CS-0886 |
| CTK7J5576 |
| D07662 |
| DB00341 |
| DTXSID4022787 |
| EN300-52521 |
| FT-0603001 |
| FT-0654660 |
| GTPL1222 |
| Hitrizin Film Tablet |
| HMS1539O07 |
| HMS3259D06 |
| HMS3370I19 |
| HMS3393N10 |
| HSDB 7739 |
| HY-17042 |
| I06-0454 |
| J-005737 |
| L000655 |
| Levocetirizine HCl |
| LS-11409 |
| MCULE-8668839822 |
| MFCD00800721 |
| MolPort-002-506-309 |
| NC00696 |
| NCGC00167781-01 |
| NCGC00167781-02 |
| NCGC00167781-03 |
| NCGC00167781-04 |
| NCGC00167781-07 |
| Prestwick0_000503 |
| Prestwick1_000503 |
| Prestwick2_000503 |
| Prestwick3_000503 |
| RT-007014 |
| SAM002548972 |
| SAM002589989 |
| SBI-0206838.P001 |
| SC-17992 |
| SC-18167 |
| SC-19204 |
| SC-19390 |
| SCHEMBL4176 |
| Setir |
| SPBio_002346 |
| ST024755 |
| STK711108 |
| TimTec1_002075 |
| U095 |
| Virlix |
| Xarlin |
| Z1182332250 |
| Ziptek |
| Zirtek |
| ZKLPARSLTMPFCP-UHFFFAOYSA-N |
| Zyrlex |
| Zyrtec Syrup |
| Zyrtec-D |
US Patents and Regulatory Information for ZERVIATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eyevance | ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694-001 | May 30, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Eyevance | ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694-001 | May 30, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Eyevance | ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694-001 | May 30, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Eyevance | ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694-001 | May 30, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for ZERVIATE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2011116020 | ➤ Sign Up |
| Japan | 6033677 | ➤ Sign Up |
| European Patent Office | 2547340 | ➤ Sign Up |
| Japan | 2016190878 | ➤ Sign Up |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for ZERVIATE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0663828 | C300085 | Netherlands | ➤ Sign Up | PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103 |
| 0058146 | 2001C/045 | Belgium | ➤ Sign Up | PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
